Burjeel Holdings has introduced artificial intelligence capabilities into its cardiac catheterization laboratories in Abu Dhabi and Sharjah, according to a report published by the Emirates News Agency. The deployment equips the labs with tools that support enhanced imaging analysis and real-time guidance during interventional procedures. Cardiovascular diseases account for 34 percent of all deaths in the UAE and this trend has accelerated investments in specialized diagnostic equipment across major providers. The timing aligns with national efforts to address comorbidities such as hypertension that affect roughly 31 percent of the population and drive procedure volumes higher each year.
The UAE artificial intelligence in cardiology market stood at 11.5 million dollars in 2025 and is projected to register a compound annual growth rate of 32.8 percent through 2033, a Grand View Research assessment found. Burjeel Holdings’ rollout forms part of this expansion as hospitals adopt systems that improve visualization and reduce procedural risks. Similar AI-enabled cath labs have demonstrated up to 30 percent gains in procedural accuracy along with 25 percent shorter patient recovery periods in documented cases from comparable markets. The company’s facilities are positioned to handle increased caseloads stemming from both local residents and medical tourists seeking high-technology cardiac services.
A Ken Research overview placed the broader UAE cath labs market near 100 million dollars in recent years with growth linked to higher numbers of diagnostic and interventional cases. Burjeel Holdings operates within this environment where advancements in catheterization technology including bioresorbable stents and AI-driven imaging have become central to competitive differentiation. The new systems at the two sites are expected to lower radiation doses for patients and clinical teams while preserving or improving image quality during complex interventions. Such features address long-standing concerns about cumulative exposure in high-volume cardiac centers.
Mordor Intelligence data shows the UAE cardiovascular devices market valued at 227.26 million dollars in 2026 with an anticipated rise to 302.31 million dollars by 2031 at a 5.87 percent compound annual growth rate. Burjeel Holdings’ integration of AI tools corresponds with the segment’s shift toward minimally invasive techniques that shorten hospital stays and support outpatient care models. The provider’s network has expanded to meet demand in key emirates where specialized cardiac units report steady increases in annual catheterizations. Officials noted that the upgraded labs will contribute to more personalized treatment pathways based on detailed real-time data.
Industry evaluations of AI applications in cardiac imaging indicate potential cost reductions of up to 20 percent through optimized resource use and fewer repeat procedures. Burjeel Holdings’ decision reflects a pattern seen across the Middle East cath labs sector which Emergen Research projected to grow from 1.2 billion dollars in 2024 to 2.5 billion dollars by 2034 at 7.5 percent annually. The Abu Dhabi and Sharjah sites will now incorporate predictive analytics that assist cardiologists in complication avoidance and stent optimization. This development adds to the group’s portfolio of technology-enhanced services aimed at elevating regional healthcare benchmarks.
The introduction of these AI-powered systems occurs as the UAE continues to attract global medical device manufacturers through regulatory reforms and free-zone incentives that facilitate rapid technology adoption. Burjeel Holdings joins other major providers investing in cath lab modernization to accommodate an aging population and rising chronic disease prevalence. Future expansions may extend similar capabilities to additional facilities as the company monitors outcomes from the initial deployments. Data from the first year of operation is expected to inform further refinements in AI-assisted cardiac protocols across the network.
